Cargando…
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/ https://www.ncbi.nlm.nih.gov/pubmed/19225538 http://dx.doi.org/10.1038/leu.2009.26 |
_version_ | 1782169430174728192 |
---|---|
author | Reeder, Craig B. Reece, Donna E. Kukreti, Vishal Chen, Christine Trudel, Suzanne Hentz, Joseph Noble, Brie Pirooz, Nicholas A. Spong, Jacy E. Piza, Jesus G. Zepeda, Victor H. Jimenez Mikhael, Joseph R. Leis, Jose F. Bergsagel, P. Leif Fonseca, Rafael Stewart, A. Keith |
author_facet | Reeder, Craig B. Reece, Donna E. Kukreti, Vishal Chen, Christine Trudel, Suzanne Hentz, Joseph Noble, Brie Pirooz, Nicholas A. Spong, Jacy E. Piza, Jesus G. Zepeda, Victor H. Jimenez Mikhael, Joseph R. Leis, Jose F. Bergsagel, P. Leif Fonseca, Rafael Stewart, A. Keith |
author_sort | Reeder, Craig B. |
collection | PubMed |
description | We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly diagnosed, symptomatic patients with multiple myeloma received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, 11, cyclophosphamide 300 mg/m(2) orally days 1, 8, 15, 22 and dexamethasone 40 mg orally days 1-4, 9-12, 17-20 on a 28 day cycle for four cycles. Responses were rapid with a mean 80% decline in the sentinel monoclonal protein at the end of two cycles. The overall intent to treat response rate (≥ partial response) was 88% with 61% ≥VGPR and 39% CR/nCR. For the 28 patients that completed all 4 cycles of therapy the CR/nCR rate was 46% and ≥VGPR rate 71%. All patients undergoing stem cell harvest had a successful collection. Twenty three patients underwent SCT and are evaluable through day 100 with CR/nCR documented in 70% and ≥VGPR in 74%. In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed multiple myeloma with manageable toxicity. |
format | Text |
id | pubmed-2711213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
record_format | MEDLINE/PubMed |
spelling | pubmed-27112132010-01-01 Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial Reeder, Craig B. Reece, Donna E. Kukreti, Vishal Chen, Christine Trudel, Suzanne Hentz, Joseph Noble, Brie Pirooz, Nicholas A. Spong, Jacy E. Piza, Jesus G. Zepeda, Victor H. Jimenez Mikhael, Joseph R. Leis, Jose F. Bergsagel, P. Leif Fonseca, Rafael Stewart, A. Keith Leukemia Article We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly diagnosed, symptomatic patients with multiple myeloma received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, 11, cyclophosphamide 300 mg/m(2) orally days 1, 8, 15, 22 and dexamethasone 40 mg orally days 1-4, 9-12, 17-20 on a 28 day cycle for four cycles. Responses were rapid with a mean 80% decline in the sentinel monoclonal protein at the end of two cycles. The overall intent to treat response rate (≥ partial response) was 88% with 61% ≥VGPR and 39% CR/nCR. For the 28 patients that completed all 4 cycles of therapy the CR/nCR rate was 46% and ≥VGPR rate 71%. All patients undergoing stem cell harvest had a successful collection. Twenty three patients underwent SCT and are evaluable through day 100 with CR/nCR documented in 70% and ≥VGPR in 74%. In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed multiple myeloma with manageable toxicity. 2009-02-19 2009-07 /pmc/articles/PMC2711213/ /pubmed/19225538 http://dx.doi.org/10.1038/leu.2009.26 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Reeder, Craig B. Reece, Donna E. Kukreti, Vishal Chen, Christine Trudel, Suzanne Hentz, Joseph Noble, Brie Pirooz, Nicholas A. Spong, Jacy E. Piza, Jesus G. Zepeda, Victor H. Jimenez Mikhael, Joseph R. Leis, Jose F. Bergsagel, P. Leif Fonseca, Rafael Stewart, A. Keith Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title | Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title_full | Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title_fullStr | Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title_full_unstemmed | Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title_short | Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial |
title_sort | cyclophosphamide, bortezomib and dexamethasone (cybord) induction for newly diagnosed multiple myeloma: high response rates in a phase ii clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/ https://www.ncbi.nlm.nih.gov/pubmed/19225538 http://dx.doi.org/10.1038/leu.2009.26 |
work_keys_str_mv | AT reedercraigb cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT reecedonnae cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT kukretivishal cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT chenchristine cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT trudelsuzanne cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT hentzjoseph cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT noblebrie cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT pirooznicholasa cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT spongjacye cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT pizajesusg cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT zepedavictorhjimenez cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT mikhaeljosephr cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT leisjosef cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT bergsagelpleif cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT fonsecarafael cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial AT stewartakeith cyclophosphamidebortezomibanddexamethasonecybordinductionfornewlydiagnosedmultiplemyelomahighresponseratesinaphaseiiclinicaltrial |